
SXTP Stock Forecast & Price Target
SXTP Analyst Ratings
Bulls say
60 Degrees Pharmaceuticals Inc. has demonstrated significant revenue growth, with FY24 net product revenues surging by 140% to $607.6 thousand and a notable increase of 223% year-over-year in Q3 FY25 net product revenue to $438 thousand. The continuous rise in ARAKODA deliveries highlights the product's strong market uptake, suggesting substantial growth potential as sales rose to 1,505 boxes in Q3 FY25 compared to 1,319 boxes a year prior. Additionally, the favorable safety profile of tafenoquine opens up opportunities for combination therapies, which could further enhance its market applicability and revenue avenues moving forward.
Bears say
60 Degrees Pharmaceuticals Inc has experienced a reduction in product revenues to $100,000 due to supply constraints, raising concerns about the company’s revenue ramp visibility. The firm reported a gross loss of approximately $9,000, a stark contrast to the gross profit of $36,000 in the previous quarter, primarily due to a one-time inventory write-off. Furthermore, uncertainties surrounding regulatory approvals for new indications and the risk of dilution from potential financing pose significant challenges to investor confidence and the company’s financial outlook.
This aggregate rating is based on analysts' research of 60 Degrees Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.
SXTP Analyst Forecast & Price Prediction
Start investing in SXTP
Order type
Buy in
Order amount
Est. shares
0 shares